

Portuguese recommendations for the use of biological therapies in patients with axial spondyloarthritis – December 2011 update

Pedro Machado, Alexandra Bernardo, Ana Rita Cravo, Ana Rodrigues, Armando Malcata, Dolores Nour, Elsa Vieira-Sousa, Fátima Godinho, Fernando Pimentel, Helena Canhão, Helena Santos, Inês Cunha, João Eurico Fonseca, José Costa, Lúcia Costa, Luís Cunha-Miranda, Luís Maurício, Margarida Cruz, Maria José Santos, Miguel Bernardes, Mónica Bogas, Paula Valente, Sofia Ramiro, Anabela Barcelos, on behalf of the Portuguese Society of Rheumatology

ACTA REUMATOL PORT. 2012;37:15-22

ABSTRACT

Objective: To develop recommendations for the treatment of axial spondyloarthritis with biological therapies, endorsed by the Portuguese Society of Rheumatology.

Methods: These treatment recommendations were formulated by Portuguese rheumatologists based on literature evidence and consensus opinion. A draft of the recommendations and supporting evidence was first circulated to all Portuguese rheumatologists and their suggestions were incorporated in the draft. Secondly, at a national meeting the recommendations were presented, discussed and revised. Finally, the document resulting from this meeting was again circulated to all Portuguese rheumatologists, who anonymously voted online on the level of agreement with the recommendations.

Results: A consensus was achieved regarding the initiation, assessment of response and switching biological therapies in patients with axial spondyloarthritis.

Conclusion: These recommendations may be used for guidance in deciding which patients with axial spondyloarthritis should be treated with biological therapies. They cover a rapidly evolving area of therapeutic intervention. As more evidence becomes available and more biological therapies are licensed, these recommendations will have to be updated.

Keywords: Portugal; Axial spondyloarthritis; Ankylosing spondylitis; Biological therapies; Guidelines.

INTRODUCTION

In 2005, the first version of the Portuguese Society of Rheumatology guidelines for the treatment of ankylo-

sing spondylitis (AS) with biological therapies was published in *Acta Reumatológica Portuguesa (ARP)*¹. Since then new evidence has been published, the concept of axial spondyloarthritis (SpA)/AS has changed and the knowledge about the use of tumour necrosis factor (TNF) antagonists has grown substantially, urging the need to revise these recommendations.

There are currently four approved biological therapies for AS and all of them are TNF antagonists: adalimumab, etanercept, golimumab and infliximab²⁻¹³. These therapies can be used in monotherapy, without the need to combine them with synthetic disease modifying anti-rheumatic drugs (DMARDs). Importantly, there is now evidence that patients with non-radiographic axial SpA also benefit from biological therapies, and that this benefit may even be greater compared to patients with radiographic axial SpA¹⁰⁻¹³.

This article presents the 2011 update of the Portuguese recommendations for the use of biological therapies in patients with axial SpA. Although these national recommendations contain some original concepts, their general structure follows the pattern of other international recommendations¹⁴. They were formulated by Portuguese rheumatologists based on literature evidence and consensus opinion. A draft of the recommendations and supporting evidence was first circulated to all Portuguese rheumatologists and their suggestions were incorporated in the draft. Secondly, at a national meeting the recommendations were presented, discussed and revised. Finally, the document resulting from this meeting was again circulated to all Portuguese rheumatologists, who anonymously voted online on the level of agreement with the recommendations. Agreement was measured on a 10-point nu-

merical rating scale (1=no agreement, 10=full agreement).

These recommendations may be used for guidance in deciding which patients with axial SpA should be treated with biological therapies. The use of biological therapies in axial SpA (and other rheumatic diseases) is a rapidly evolving field and as more evidence becomes available and more biological therapies are licensed, these recommendations will have to be updated.

CRITERIA FOR STARTING BIOLOGICAL THERAPIES AND ASSESSING RESPONSE TO TREATMENT

GENERAL STATEMENT

RECOMMENDATION 1: In axial SpA, biological therapies are recommended for patients with active disease despite optimal conventional treatment (treatment failure).

DIAGNOSIS OF AXIAL SPA

RECOMMENDATION 2: Patients are classified as having axial SpA if they fulfill the Assessment of Spondyloarthritis international Society (ASAS) criteria for axial SpA or the modified New York criteria for AS.

In the 2005 consensus statement, it had already been recognized that the modified New York (mNY) criteria for AS were restrictive and did not cover the whole spectrum of patients with axial SpA. At that time, a modification of the mNY criteria was proposed, allowing the definition of sacroiliitis not only according to the findings observed on plain radiographs but also according to other imaging methods, namely magnetic resonance imaging (MRI) or computed tomography (CT)¹.

It is now widely recognized that the mNY criteria perform well in established disease but lack sensitivity in early spinal disease. Furthermore, over the last years MRI has become the preferred imaging method in assessing patients with suspected early disease who do not yet have definite sacroiliitis on plain radiographs as required by the mNY criteria¹⁵.

On MRI, active inflammation of the sacroiliac joints with or without signs of structural damage can be anatomically accurately visualized. Importantly, MRI performs better than radioisotope scintigraphy (which has limited diagnostic value)¹⁶ and CT (which is associated with higher radiation exposure and cannot visual-

ize active inflammation, although it can better detect structural lesions of the sacroiliac joints such as erosions)¹⁷. Active sacroiliitis on MRI has also been shown to predict the later appearance of sacroiliitis on radiographs^{18,19}, thereby adding validity to the identification of inflammation of the sacroiliac joints on MRI as an important finding in early axial SpA^{15,20}.

These new developments led to the concept of “axial SpA” that serves as an umbrella for patients with definite radiographic sacroiliitis, that is AS, and for patients without definite radiographic sacroiliitis, referred to as non-radiographic axial SpA¹⁵. This new paradigm has led the ASAS group to develop new criteria for axial SpA, published in 2009^{21,22}. The new criteria allow classifying patients as having axial SpA in the absence of radiographic sacroiliitis and therefore in earlier disease stages. Importantly, it has also been shown that patients with non-radiographic axial SpA have similar disease burden as patients fulfilling the mNY criteria²³. Furthermore, studies with TNF antagonists in patients with early/non-radiographic axial SpA¹⁰⁻¹³ have shown at least similar efficacy to, and, in part, better efficacy than, studies in patients fulfilling mNY criteria²⁻⁹.

DEFINITION OF ACTIVE DISEASE

RECOMMENDATION 3: Active axial disease candidate to biological therapy is defined by a BASDAI ≥ 4 or ASDAS ≥ 2.1 , in two separate occasions with at least 1 month interval. The decision to treat with biological therapy should be supported by the rheumatologist's opinion.

Historically, the Bath AS Disease Activity Index (BASDAI)²⁴ has been the most widely used clinical disease activity measure in axial SpA, and the BASDAI cut-off ≥ 4 the most common selection criteria for clinical trials with TNF antagonists. The AS Disease Activity Score (ASDAS)²⁵⁻²⁸ is a new composite index recently developed for axial SpA, with validated disease activity cut-offs (an ASDAS ≥ 2.1 represents high disease activity).

The inclusion of the ASDAS as an alternative to the BASDAI to define active axial disease was based on the good psychometric properties of this new index²⁸ and its recent validation among the Outcome Measures in Rheumatology (OMERACT) community²⁹. There is also recent evidence that the ASDAS may better reflect the inflammatory disease processes in patients with axial SpA³⁰ and that ASDAS high disease activity (ASDAS ≥ 2.1) may be a better cut-off than BASDAI elevation (BASDAI ≥ 4) to select patients for treatment with

TNF antagonists³¹⁻³³, namely because it selects a higher number of patients with characteristics predictive of good response to these therapies^{31,34}.

The decision to consider the disease as active should be supported by the rheumatologist's opinion, who should base his judgment on clinical, laboratorial (acute phase reactants) and imaging (radiographs, MRI) features of the disease.

DEFINITION OF TREATMENT FAILURE:

RECOMMENDATION 4: Treatment failure is defined as active disease despite a continuous therapeutic trial with at least two NSAIDs over at least a 2-week period each at maximum recommended anti-inflammatory doses, unless contraindicated or if the patient develops intolerance or side-effects. For axial disease, no additional treatment with synthetic DMARDs is required before initiation of therapy with a TNF antagonist.

Patients with peripheral arthritis should have an adequate trial (at least three months of full dose treatment) with a synthetic DMARD (preferably sulfasalazine), unless contraindicated or if the patient develops intolerance or side-effects. In the case of monoarthritis or oligoarthritis (≤ 4 joints) at least one intra-articular injection with corticosteroids should also have been tried, as long as there is no contraindication.

For symptomatic enthesitis, at least one local steroid injection is required, as long as there is no contraindication.

NSAIDs (classical or COX-2 inhibitors) have demonstrated clinical efficacy in axial disease³⁵⁻⁴⁰, contrary to synthetic DMARDs, for which there is no evidence of clinical efficacy⁴¹⁻⁴³.

All patients should have an adequate therapeutic trial of at least two NSAIDs over at least a 2-week period each, corresponding to a total of at least 4 weeks of full-dose continuous NSAID treatment, unless contraindicated or if the patient develops intolerance or side-effects. The literature about the length of time beyond which it would be unlikely that a NSAID would be effective is scarce. Only a few trials provided detailed information on the time course of efficacy and these trials suggest that the maximum effect is achieved after 2 weeks^{36,37}. However, the evidence for recommending this treatment period is limited and there are patients that may still respond after 2 weeks of treatment. Therefore, the rheumatologist may choose to expand this treatment period for each NSAID.

There are studies suggesting some efficacy of sulfasalazine in peripheral disease and in the prevention of anterior uveitis⁴¹⁻⁴³. Regarding methotrexate and leflunomide, data are very limited and there is no evidence of efficacy in peripheral disease^{44,45}. However, it was recognized that methotrexate is often prescribed in SpA patients with peripheral arthritis, but no evidence based recommendation can presently support this treatment.

ASSESSMENT OF RESPONSE TO TREATMENT

RECOMMENDATION 5: Response to treatment should be assessed after at least 3 months of continuous treatment with a biological therapy. Response criteria are: 1) a decrease in BASDAI $\geq 50\%$ or ≥ 2 units (0-10 scale) or 2) a decrease in ASDAS ≥ 1.1 units.

The choice of at least a 3-month interval as the time for evaluation of response to a biological agent was based on observations from phase III trials with TNF antagonists, where response rates stabilized from 3 months onwards¹⁴. The inclusion of the ASDAS response as an alternative to the BASDAI response in assessing efficacy of the biological therapy was based on the improved psychometric properties of the ASDAS compared to the BASDAI^{25-28,33} and its recent validation among the OMERACT community²⁹. Furthermore, there is recent evidence that the ASDAS may better reflect the inflammatory disease processes in patients with axial SpA than the BASDAI³⁰.

PROCEDURE IN CASE OF INADEQUATE RESPONSE TO A BIOLOGICAL AGENT

RECOMMENDATION 6: After an adequate dose and length of treatment, we recommend switching the biological therapy in non-respondent patients. Patients have been switched successfully from one TNF antagonist to another. There are several studies confirming a significant response to a second or third TNF antagonist⁴⁶⁻⁵². A reduced response is seen more frequently in patients who switched because of inefficacy when compared with patients who switched due to adverse events⁴⁸. Furthermore, patients with secondary loss of response (in which antibody formation may be involved) seem to have a higher potential for response to a TNF antagonist switch than patients who are primary non-responders^{53,54}. There is no evidence that a dose increase or a decrease in dose interval enhances response.

PROCEDURE IN CASE OF SUSTAINED LONG-TERM REMISSION UNDER A BIOLOGICAL AGENT

RECOMMENDATION 7: In case of a good response to biological therapy there is no evidence for recommending a dose reduction or the interruption of the treatment, however this can be considered in selected patients in a remission-like state for more than 12 months.

There is no evidence for recommending a dose reduction or the interruption of the biological treatment⁵⁵⁻⁶². However, tapering biological therapy (expanding the interval between doses or reducing the dose, and eventually discontinuing treatment) may be considered in individualized cases, namely patients with ASDAS inactive disease²⁷ and/or ASAS partial remission criteria⁶³ for at least 12 months^{57,58,61,64-66}. This approach should be thoroughly discussed with the patient and supported by the rheumatologist opinion. In such cases, a short-term reassessment of the need of treatment reintroduction should be planned. It should be noted that most patients flare after discontinuation of treatment but the reintroduction of treatment seems safe and effective⁵⁵⁻⁶².

CLINICAL ASSESSMENT

The following should be considered for clinical assessment of patients with axial SpA:

- a) Disease activity: BASDAI^{24,67}, ASDAS (preferably ASDAS with C-reactive protein [CRP], alternatively ASDAS with erythrocyte sedimentation rate [ESR])²⁵⁻²⁷, patient global assessment (visual analogue scale [VAS] or 0-10 numeric rating scale [NRS]), physician global assessment (VAS or 0-10 NRS), spinal pain in the last week (VAS or 0-10 NRS), spinal night pain in the last week (VAS or 0-10 NRS) and CRP or ESR. Where there is peripheral arthritis or enthesitis, appropriate joint counts and number of symptomatic entheses should be recorded.
- b) Physical function should be assessed by the Bath Ankylosing Spondylitis Functional Index (BASFI)^{67,68}. Where there is peripheral arthritis or enthesitis, the Health Assessment Questionnaire (HAQ) disability questionnaire may provide additional useful information⁶⁹. A modification of the Health Assessment Questionnaire for the spondyloarthritis (HAQ-S) may be used as an alternative to the BASFI⁷⁰.
- c) Spinal mobility should be assessed by the Bath An-

kylosing Spondylitis Metrology Index (BASMI)⁷¹⁻⁷³, occiput to wall distance and chest expansion.

- d) Health related quality of life should be assessed by specific (Ankylosing Spondylitis Quality of Life [AS-QoL])⁷⁴ or generic questionnaires (Short Form 36 [SF-36] or Short Form 12 [SF-12])⁷⁵⁻⁷⁷.

A register of patients with rheumatic diseases (Reuma.pt) has been established in Portugal since 2008⁷⁸. This registry includes standardized disease assessment tools for inflammatory rheumatic diseases, including axial SpA. All patients selected for treatment with biological therapies should be included in Reuma.pt⁷⁸.

TUBERCULOSIS SCREENING BEFORE INTRODUCTION OF BIOLOGICAL THERAPIES

The Portuguese Society of Rheumatology (SPR) and the Portuguese Society of Pneumology (SPP) have developed recommendations on the diagnosis and treatment of latent tuberculosis and active tuberculosis in patients with inflammatory joint diseases treated with biologic therapies, which are periodically updated and available at the SPR, SPP and *Direcção-Geral da Saúde* websites⁷⁹.

“ABSOLUTE” CONTRAINDICATIONS FOR THE USE OF BIOLOGICAL THERAPIES

1. Active infection (some exceptions can be considered and this issue is detailed in the practical guide for prescribing biological therapies published by SPR⁸⁰).
2. Concurrent administration of live vaccines.
3. Recent history (<5 years) of malignancy (except in the case of basal cell carcinoma).
4. Congestive heart failure (NYHA class III-IV).
5. History of demyelinating disease.

PREGNANCY AND THE USE OF BIOLOGICAL THERAPIES

1. Biological therapy should not be started in pregnant or breastfeeding women.
2. If pregnancy occurs under treatment, biological therapy should be stopped.

This issue is detailed in the practical guide for prescribing biological therapies published by SPR⁸⁰ and in a recently published systematic literature review⁸¹.

TABLE I. RECOMMENDATIONS FOR THE USE OF BIOLOGICAL THERAPIES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS

Domain	Recommendation	Agreement mean (SD)
General recommendation	In axial SpA, biological therapies are recommended for patients with active disease despite optimal conventional treatment (treatment failure)	9.5 (0.8)
Classification of patients	Patients are classified as having axial SpA if they fulfill the ASAS criteria for axial SpA or the modified New York criteria for AS	9.0 (1.5)
Active disease	Active axial disease candidate to biological therapy is defined by a BASDAI ≥ 4 or ASDAS ≥ 2.1 , in two separate occasions with at least 1 month interval. The decision to treat with biological therapy should be supported by the rheumatologist's opinion	8.9 (1.8)
Treatment failure	Treatment failure is defined as active disease despite a continuous therapeutic trial with at least two NSAIDs over at least a 2-week period each at maximum recommended anti-inflammatory doses, unless contraindicated or if the patient develops intolerance or side-effects. For axial disease, no additional treatment with synthetic DMARDs is required before initiation of therapy with a TNF antagonist. Patients with peripheral arthritis should have an adequate trial (at least three months of full dose treatment) with a synthetic DMARD (preferably sulfasalazine), unless contraindicated or if the patient develops intolerance or side-effects. In the case of monoarthritis or oligoarthritis (≤ 4 joints) at least one intra-articular injection with corticosteroids should also have been tried, as long as there is no contraindication. For symptomatic enthesitis, at least one local steroid injection is required, as long as there is no contraindication	8.0 (2.2)
Assessment of response	Response to treatment should be assessed after at least 3 months of continuous treatment with a biological therapy. Response criteria are: 1) a decrease in BASDAI $\geq 50\%$ or ≥ 2 units (0-10 scale) or 2) a decrease in ASDAS ≥ 1.1 units	9.0 (1.3)
Inadequate response	After an adequate dose and length of treatment, we recommend switching the biological therapy in non-respondent patients	9.2 (1.0)
Long-term "remission"	In case of a good response to biological therapy there is no evidence for recommending a dose reduction or the interruption of the treatment, however this can be considered in selected patients in a remission-like state for more than 12 months	8.8 (1.4)

Agreement was voted on a scale from 1 to 10 (fully disagree to fully agree) by 38 voting rheumatologists.

AS, ankylosing spondylitis. ASAS, Assessment of Spondyloarthritis international Society. ASDAS, Ankylosing Spondylitis Disease Activity Score. BASDAI, Bath Ankylosing Spondylitis Disease Activity Index. DMARD, disease-modifying antirheumatic drug. NSAID, non-steroidal anti-inflammatory drug. SD, standard deviation. TNF, tumour necrosis factor.

CRITERIA FOR TEMPORARY SUSPENSION/ /POSTPONEMENT OF INTRODUCTION OF BIOLOGICAL THERAPIES

1. Active infection.
 2. Recurrent infection or high risk for infections.
 3. Major surgery planned.
- This issue is detailed in the practical guide for pres-

cribing biological therapies published by SPR⁸⁰ and in a recent review⁸².

CORRESPONDENCE TO

Pedro Machado
Serviço de Reumatologia, Hospitais da Universidade de Coimbra
Praceta Prof. Mota Pinto
3000-075 Coimbra, Portugal
Email: pedrommcmachado@gmail.com

REFERENCES

1. Grupo de Consensos para as Terapêuticas Biológicas na Espondilite Anquilosante da Sociedade Portuguesa de Reumatologia. Consensos sobre a utilização de antagonistas do TNF- α na terapêutica da espondilite anquilosante. *Acta Reumatol Port* 2005;30:155-159.
2. Davis JC, Jr., Van Der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. *Arthritis Rheum* 2003;48:3230-3236.
3. van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). *Arthritis Rheum* 2005;52:582-591.
4. van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. *Arthritis Rheum* 2006;54:2136-2146.
5. Davis JC, Jr., van der Heijde DM, Braun J, et al. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. *Ann Rheum Dis* 2008;67:346-352.
6. Braun J, Baraliakos X, Listing J, et al. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. *Ann Rheum Dis* 2008;67:340-345.
7. van der Heijde D, Pangan AL, Schiff MH, et al. Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis. *Ann Rheum Dis* 2008;67:1218-1221.
8. van der Heijde D, Schiff MH, Sieper J, et al. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. *Ann Rheum Dis* 2009;68:922-929.
9. Inman RD, Davis JC, Jr., Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. *Arthritis Rheum* 2008;58:3402-3412.
10. Haibel H, Rudwaleit M, Listing J, et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. *Arthritis Rheum* 2008;58:1981-1991.
11. Song IH, Hermann K, Haibel H, et al. Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. *Ann Rheum Dis* 2011;70:590-596.
12. Barkham N, Keen HI, Coates LC, et al. Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis. *Arthritis Rheum* 2009;60:946-954.
13. Sieper J, der Heijde D, Dougados M, et al. Efficacy and Safety of Adalimumab in Patients with Non-Radiographic Axial Spondyloarthritis – Results From a Phase 3 Study. 2011 Annual Scientific Meeting of the American College of Rheumatology (Presentation 2486A).
14. van der Heijde D, Sieper J, Maksymowych WP, et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. *Ann Rheum Dis* 2011;70:905-908.
15. Rudwaleit M. New approaches to diagnosis and classification of axial and peripheral spondyloarthritis. *Curr Opin Rheumatol* 2010;22:375-380.
16. Song IH, Carrasco-Fernandez J, Rudwaleit M, Sieper J. The diagnostic value of scintigraphy in assessing sacroiliitis in ankylosing spondylitis: a systematic literature research. *Ann Rheum Dis* 2008;67:1535-1540.
17. Geijer M, Gadeholt Gothlin G, Gothlin JH. The validity of the New York radiological grading criteria in diagnosing sacroiliitis by computed tomography. *Acta Radiol* 2009;50:664-673.
18. Oostveen J, Prevo R, den Boer J, van de Laar M. Early detection of sacroiliitis on magnetic resonance imaging and subsequent development of sacroiliitis on plain radiography. A prospective, longitudinal study. *J Rheumatol* 1999;26:1953-1958.
19. Bennett AN, McGonagle D, O'Connor P, et al. Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years. *Arthritis Rheum* 2008;58:3413-3418.
20. Rudwaleit M, Jurik AG, Hermann KG, et al. Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. *Ann Rheum Dis* 2009;68:1520-1527.
21. Rudwaleit M, Landewe R, van der Heijde D, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. *Ann Rheum Dis* 2009;68:770-776.
22. Rudwaleit M, van der Heijde D, Landewe R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. *Ann Rheum Dis* 2009;68:777-783.
23. Rudwaleit M, Haibel H, Baraliakos X, et al. The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. *Arthritis Rheum* 2009;60:717-727.
24. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. *J Rheumatol* 1994;21:2286-2291.
25. Lukas C, Landewe R, Sieper J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. *Ann Rheum Dis* 2009;68:18-24.
26. van der Heijde D, Lie E, Kvien TK, et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. *Ann Rheum Dis* 2009;68:1811-1818.
27. Machado P, Landewe R, Lie E, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. *Ann Rheum Dis* 2011;70:47-53.
28. Machado P, van der Heijde D. How to measure disease activity in axial spondyloarthritis? *Curr Opin Rheumatol* 2011;23:339-345.
29. Machado PM, Landewe RB, van der Heijde DM. Endorsement of Definitions of Disease Activity States and Improvement Scores for the Ankylosing Spondylitis Disease Activity Score: Results from OMERACT 10. *J Rheumatol* 2011;38:1502-1506.

30. Pedersen SJ, Hetland ML, Sorensen IJ, Ostergaard M, Nielsen HJ, Johansen JS. Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total aggrecan in spondyloarthritis patients during 3 years of treatment with TNFalpha inhibitors. *Clin Rheumatol* 2010;29:1301-1309.
31. Vastesaegeer N, van der Cruyssen B, Mulero J, et al. ASDAS high disease activity may be a better selection criterion than BASDAI elevation for the treatment of ankylosing spondylitis patients with anti-NF therapy. 2011 Annual Congress of the European League Against Rheumatism:OP0175.
32. Fagerli KM, Lie E, van der Heijde D, et al. Selection of Patients with Ankylosing Spondylitis for TNF-Inhibitor Therapy: Comparing Responses in Patients Selected by BASDAI & ASDAS. 2011 Annual Scientific Meeting of the American College of Rheumatology (Presentation 2486A).
33. Arends S, Brouwer E, van der Veer E, et al. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. *Arthritis Res Ther* 2011;13:R94.
34. Vastesaegeer N, van der Heijde D, Inman RD, et al. Predicting the outcome of ankylosing spondylitis therapy. *Ann Rheum Dis* 2011;70:973-981.
35. Escalas C, Trijau S, Dougados M. Evaluation of the treatment effect of NSAIDs/TNF blockers according to different domains in ankylosing spondylitis: results of a meta-analysis. *Rheumatology (Oxford)* 2010;49:1317-1325.
36. van der Heijde D, Baraf HS, Ramos-Remus C, et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. *Arthritis Rheum* 2005;52:1205-1215.
37. Sieper J, Klopsch T, Richter M, et al. Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study. *Ann Rheum Dis* 2008;67:323--329.
38. Jarrett SJ, Sivera F, Cawkwell LS, et al. MRI and clinical findings in patients with ankylosing spondylitis eligible for anti-tumour necrosis factor therapy after a short course of etoricoxib. *Ann Rheum Dis* 2009;68:1466-1469.
39. Wanders A, Heijde D, Landewe R, et al. Nonsteroidal anti-inflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. *Arthritis Rheum* 2005;52:1756-1765.
40. El Miedany Y, Youssef S, Ahmed I, El Gaafary M. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. *Am J Gastroenterol* 2006;101:311-317.
41. Chen J, Liu C. Sulfasalazine for ankylosing spondylitis. *Cochrane Database Syst Rev* 2005:CD004800.
42. Braun J, Zochling J, Baraliakos X, et al. Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. *Ann Rheum Dis* 2006; 65:1147-1153.
43. Braun J, van der Horst-Bruinsma IE, Huang F, et al. Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. *Arthritis Rheum* 2011;63:1543-1551.
44. Chen J, Liu C, Lin J. Methotrexate for ankylosing spondylitis. *Cochrane Database Syst Rev* 2006:CD004524.
45. Haibel H, Brandt HC, Song IH, et al. No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial. *Ann Rheum Dis* 2007;66:419-421.
46. Cantini F, Niccoli L, Benucci M, et al. Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: results of a fifty-four-week study. *Arthritis Rheum* 2006;55:812-816.
47. Coates LC, Cawkwell LS, Ng NW, et al. Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis. *Rheumatology (Oxford)* 2008;47:897-900.
48. Pradeep DJ, Keat AC, Gaffney K, Brooksby A, Leeder J, Harris C. Switching anti-TNF therapy in ankylosing spondylitis. *Rheumatology (Oxford)* 2008;47:1726-1727.
49. Dadoun S, Geri G, Paternotte S, Dougados M, Gossec L. Switching between tumour necrosis factor blockers in spondyloarthritis: a retrospective monocentre study of 222 patients. *Clin Exp Rheumatol* 2011.
50. Conti F, Ceccarelli F, Marocchi E, et al. Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period. *Ann Rheum Dis* 2007;66:1393-1397.
51. Lie E, van der Heijde D, Uhlig T, et al. Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register. *Ann Rheum Dis* 2011;70:157-163.
52. Delaunay C, Farrenq V, Marini-Portugal A, Cohen JD, Chevalier X, Claudepierre P. Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data. *J Rheumatol* 2005;32:183-185.
53. de Vries MK, Wolbink GJ, Stapel SO, et al. Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. *Ann Rheum Dis* 2007;66:1252-1254.
54. de Vries MK, Brouwer E, van der Horst-Bruinsma IE, et al. Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation. *Ann Rheum Dis* 2009;68:1787-1788.
55. Sidiropoulos P, Kritikos HD, Siakka P, et al. Low dose of infliximab is inadequate in most patients with spondylarthropathies. *Clin Exp Rheumatol* 2005;23:513-516.
56. Brandt J, Listing J, Haibel H, et al. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. *Rheumatology (Oxford)* 2005;44:342-348.
57. Baraliakos X, Listing J, Brandt J, et al. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. *Arthritis Res Ther* 2005;7:R439-44.
58. Baraliakos X, Listing J, Rudwaleit M, et al. Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis. *J Rheumatol* 2007;34:510-515.
59. Navarro-Compan V, Moreira V, Ariza-Ariza R, Hernandez-Cruz B, Vargas-Lebron C, Navarro-Sarabia F. Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease. *Clin Rheumatol* 2011;30:993-996.
60. Torrente V, Gratacos J, Juanola X, Sanmarti R, Suarez D, Moreno M. Infliximab withdrawal in patients with spondyloarthritis who presented criteria of clinical disease remission. An open study of clinical practise (REMINEA). 2009 Annual Scientific Meeting of the American College of Rheumatology (Presentation 1785).

61. Jois RN, Leeder J, Gibb A, et al. Low-dose infliximab treatment for ankylosing spondylitis—clinically- and cost-effective. *Rheumatology (Oxford)* 2006;45:1566-1569.
62. Song I-H, Hermann K-G, Haibel H, et al. Frequency and duration of drug-free remission after one year of treatment with etanercept vs. sulfasalazine in early axial spondyloarthritis – 2 year data of the ESTHER trial. 2011 Annual Scientific Meeting of the American College of Rheumatology (Presentation 2534).
63. Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. *Arthritis Rheum* 2001;44:1876-1886.
64. Vinagre F, Santos MJ, Silva JC. [Flexibilization of infliximab dose interval in the treatment of ankylosing spondylitis]. *Acta Reumatol Port* 2007;32:271-273.
65. Sieper J. Infliximab therapy for patients with ankylosing spondylitis: on-demand or continuous treatment? *Nat Clin Pract Rheumatol* 2008;4:398-399.
66. Keeling S, Oswald A, Russell AS, Maksymowych WP. Prospective observational analysis of the efficacy and safety of low-dose (3 mg/kg) infliximab in ankylosing spondylitis: 4-year follow-up. *J Rheumatol* 2006;33:558-561.
67. Pimentel-Santos FM, Pinto T, Santos H, et al. Portuguese version of the bath indexes for ankylosing spondylitis patients: a cross-cultural adaptation and validation. *Clin Rheumatol* 2011.
68. Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. *J Rheumatol* 1994;21:2281-2285.
69. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. *Arthritis Rheum* 1980;23:137-145.
70. Daltroy LH, Larson MG, Roberts NW, Liang MH. A modification of the Health Assessment Questionnaire for the spondyloarthropathies. *J Rheumatol* 1990;17:946-950.
71. Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. *J Rheumatol* 1994;21:1694-1698.
72. van der Heijde D, Landewe R, Feldtkeller E. Proposal of a linear definition of the Bath Ankylosing Spondylitis Metrology Index (BASMI) and comparison with the 2-step and 10-step definitions. *Ann Rheum Dis* 2008;67:489-493.
73. Jones SD, Porter J, Garrett SL, Kennedy LG, Whitelock H, Calin A. A new scoring system for the Bath Ankylosing Spondylitis Metrology Index (BASMI). *J Rheumatol* 1995;22:1609.
74. Doward LC, Spoorenberg A, Cook SA, et al. Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. *Ann Rheum Dis* 2003;62:20-26.
75. Ferreira PL. Criação da versão portuguesa do MOS SF-36. Parte I – Adaptação cultural e linguística. *Acta Med Port* 2000 13:55-66.
76. Ferreira PL. Criação da versão portuguesa do MOS SF-36. Parte II – Testes de validação. *Acta Med Port* 2000 13:119-127.
77. Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Med Care* 1992;30:473-483.
78. Canhao H, Faustino A, Martins F, Fonseca JE. Reuma.pt - the rheumatic diseases portuguese register. *Acta Reumatol Port* 2011;45-56.
79. Fonseca JE, Lucas H, Canhao H, et al. Recommendations for the diagnosis and treatment of latent and active tuberculosis in inflammatory joint diseases candidates for therapy with tumor necrosis factor alpha inhibitors: March 2008 update. *Acta Reumatol Port* 2008;33:77-85.
80. Mourão AF, Fonseca JE, Canhão H, et al. Practical guide for the use of biological agents in rheumatoid arthritis - December 2011 update. *Acta Reumatol Port* 2011;36:389-395.
81. Bogas M, Leandro MJ. Biologic therapy and pregnancy. A systematic literature review. 2011; *Acta Reumatol Port*:219-232.
82. Nunes J, Marinho RT, Fonseca JE, Pereira da Silva JA, Velosa J. Prophylaxis of hepatitis B reactivation with immunosuppressive therapy in rheumatic diseases. Orientations for clinical practice. *Acta Reumatol Port* 2011;36:110-118.